Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06243432
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-01-24
Brief Title:
Estrogen Receptors and HER2 Levels Expression in Luminal Metastatic Breast Cancer
Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study Overview
Official Title:
Estrogen Receptors and HER2 Levels Expression in Luminal Metastatic Breast Cancer Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase InhibitorsCDK46 as First Line Treatment CYCLHER Study
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CYCLHER
Brief Summary:
CYCLHER is a retrospective observational multicentric italian study aimed to evaluate the correlation between hormone receptors HR and HER2 immunohistochemistry IHC levels and treatmentresponse in patients affected by advanced breast cancer treated with first line CDK46 inhibitor plus endocrine therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None